Adaptive Biotechnologies officer sells 39,741 shares

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.

On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 10 txns

Insider LO FRANCIS

Role Chief People Officer

Sold 39,741 shs ($695K)

Approx. gross sale proceeds $695K

Approx. exercise cost $173K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	5,792	$0.00	$0.00
Exercise	Stock Option (right to buy)	2,009	$0.00	$0.00
Exercise	Stock Option (right to buy)	2,344	$0.00	$0.00
Exercise	Stock Option (right to buy)	9,376	$0.00	$0.00
Exercise	Common Stock	5,792	$12.14	$70K
Exercise	Common Stock	2,009	$8.46	$17K
Exercise	Common Stock	2,344	$3.99	$9K
Exercise	Common Stock	9,376	$8.12	$76K
Sale	Common Stock	39,741	$17.49	$695K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 483,489 contracts (Direct); Common Stock — 250,934 shares (Direct); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))

Footnotes (5)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2. The option is fully vested and exercisable.
F3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Key Figures

Shares sold: 39,741 shares Sale price: $17.49 per share Options exercised: 19,521 shares +4 more

7 metrics

Shares sold 39,741 shares Common Stock open-market sale on June 4, 2026 at $17.49

Sale price $17.49 per share Average price for 39,741 Common Stock shares sold

Options exercised 19,521 shares Total Common Stock from option exercises on June 4, 2026

Post-transaction direct holdings 250,934 shares Common Stock directly held by Francis Lo after transactions

Indirect holdings via spouse 2,500 shares Common Stock held by spouse, reported as indirect ownership

Lowest option strike $3.99 per share One of the stock option exercise prices

Highest option strike $12.14 per share One of the stock option exercise prices

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), Chief People Officer

4 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

Chief People Officer financial

"officer_title": "Chief People Officer""

A chief people officer is a senior executive responsible for overseeing a company's workforce and human resources strategies. They focus on attracting, developing, and retaining employees, ensuring a positive workplace culture, and aligning staff efforts with the company's goals. For investors, this role matters because strong leadership in managing people can drive productivity, innovation, and overall company performance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADPT Chief People Officer Francis Lo report?

Francis Lo reported option exercises and an open-market sale of Adaptive Biotechnologies Corp Common Stock. He exercised options for 19,521 shares, then sold 39,741 shares at $17.49 per share, with all activity occurring on June 4, 2026 under a trading plan.

How many Adaptive Biotechnologies (ADPT) shares did Francis Lo sell?

Francis Lo sold 39,741 shares of Adaptive Biotechnologies Corp Common Stock. The transaction was an open-market sale at an average price of $17.49 per share on June 4, 2026, as disclosed in the Form 4 filing.

How many ADPT shares does Francis Lo hold after these transactions?

After the reported transactions, Francis Lo holds 250,934 Adaptive Biotechnologies Corp Common Stock shares directly. In addition, 2,500 shares are held indirectly through his spouse, providing a combined view of his direct and spousal-related ownership following the June 2026 activity.

Were Francis Lo’s Adaptive Biotechnologies trades under a Rule 10b5-1 plan?

Yes. The Form 4 states that the transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such plans pre-schedule trades, indicating the timing of these June 2026 transactions was established in advance rather than decided opportunistically.

What stock options did Francis Lo exercise in this ADPT Form 4?

Francis Lo exercised options covering 19,521 shares of Adaptive Biotechnologies Corp Common Stock. The exercised options had strike prices including $3.99, $8.12, $8.46, and $12.14 per share, converting these derivative positions into common shares on June 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 08:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		M⁽¹⁾		5,792	A	$12.14	276,946	D
Common Stock	06/04/2026		M⁽¹⁾		2,009	A	$8.46	278,955	D
Common Stock	06/04/2026		M⁽¹⁾		2,344	A	$3.99	281,299	D
Common Stock	06/04/2026		M⁽¹⁾		9,376	A	$8.12	290,675	D
Common Stock	06/04/2026		S⁽¹⁾		39,741	D	$17.49	250,934	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$12.14	06/04/2026		M⁽¹⁾			5,792	⁽²⁾	03/04/2032	Common Stock	5,792	$0	171,823	D
Stock Option (right to buy)	$8.46	06/04/2026		M⁽¹⁾			2,009	⁽³⁾	03/06/2033	Common Stock	2,009	$0	85,065	D
Stock Option (right to buy)	$3.99	06/04/2026		M⁽¹⁾			2,344	⁽⁴⁾	03/04/2034	Common Stock	2,344	$0	85,953	D
Stock Option (right to buy)	$8.12	06/04/2026		M⁽¹⁾			9,376	⁽⁵⁾	03/04/2035	Common Stock	9,376	$0	140,648	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The option is fully vested and exercisable.

3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

5. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR